Which medication is considered first-line therapy for schizophrenia in this material?

Which medication is considered first-line therapy for schizophrenia in this material?

• A. Haloperidol
• B. Olanzapine
• C. Risperidone
• D. Clozapine

Answer: (B)

The idea behind first-line therapy for schizophrenia is to start a medication that effectively controls psychotic symptoms while keeping side effects manageable, so patients can return to functioning and adhere to treatment. Second-generation antipsychotics are often preferred over older, typical agents for this reason, since they generally cause fewer movement disorders and other EPS. In this material, olanzapine is identified as the first-line option because it tends to offer strong efficacy against both positive symptoms (like hallucinations and delusions) and negative symptoms, with a tolerability profile that supports good early adherence for many patients. It also can help with agitation in acute settings. However, it’s important to remember that olanzapine carries a notable risk of metabolic side effects—weight gain, insulin resistance, and lipid changes—so monitoring for metabolic health is essential. Comparatively, haloperidol is a typical antipsychotic with a higher risk of extrapyramidal symptoms; clozapine is typically reserved for treatment-resistant cases due to the risk of agranulocytosis and the need for regular blood monitoring; risperidone is another second-generation option and can be used as a first-line agent in many guidelines, but the material here designates olanzapine as the initial choice.

The idea behind first-line therapy for schizophrenia is to start a medication that effectively controls psychotic symptoms while keeping side effects manageable, so patients can return to functioning and adhere to treatment. Second-generation antipsychotics are often preferred over older, typical agents for this reason, since they generally cause fewer movement disorders and other EPS.

In this material, olanzapine is identified as the first-line option because it tends to offer strong efficacy against both positive symptoms (like hallucinations and delusions) and negative symptoms, with a tolerability profile that supports good early adherence for many patients. It also can help with agitation in acute settings. However, it’s important to remember that olanzapine carries a notable risk of metabolic side effects—weight gain, insulin resistance, and lipid changes—so monitoring for metabolic health is essential.

Comparatively, haloperidol is a typical antipsychotic with a higher risk of extrapyramidal symptoms; clozapine is typically reserved for treatment-resistant cases due to the risk of agranulocytosis and the need for regular blood monitoring; risperidone is another second-generation option and can be used as a first-line agent in many guidelines, but the material here designates olanzapine as the initial choice.